马瓦卡门:一种用于阻塞性多变性心肌病的第一类肌抑制剂
Eugene Braunwald1,2, Sara Saberi3, Theodore P Abraham4
1Division of Cardiovascular Medicine, TIMI Study Group, Brigham and Women's Hospital, 60 Fenwood Road, Boston, MA 02115, USA.
European heart journal
|October 7, 2023
概括
马瓦卡门是一种新型心脏肌酸酶抑制剂,通过降低超收缩性,有效治疗阻塞性多变性心肌病 (oHCM). 临床试验表明它可以改善症状,运动能力和心脏功能,为oHCM患者提供新的治疗选择.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阻塞性多变性心肌病 (oHCM) 具有超收缩性表型的特征.
- 目前对oHCM的治疗有局限性.
研究的目的:
- 审查mavacamten对症状性oHCM的疗效和安全性数据.
- 评估 mavacamten 在当前的 oHCM 管理中的作用.
主要方法:
- 对2期和3期临床试验数据的审查.
- 分析患者报告的结果,生物标志物和成像研究.
主要成果:
- 马瓦卡门在有症状的oHCM患者中耐受性良好.
- 显著减少左心室外流通道梯度和提高运动能力.
- 有有利的心脏改造的证据,减少了对隔膜缩小治疗的需要.
结论:
- 马瓦卡门是对症状性oHCM的第一类治疗方法,显示出显著的临床益处.
- 需要进一步的研究来确定其长期作用和疾病修饰潜力.
相关概念视频
Cardiomyopathy III: Hypertrophic Cardiomyopathy
16
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
Cardiomyopathy IV: Restrictive Cardiomyopathy
12
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
12
Cardiomyopathy V: Interprofessional Care
14
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14
Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Cardiomyopathy I: Introduction and Classification
14
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
14
Heart Failure Drugs: Inotropic Agents
601
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
601


